Table 1 Application of apoptotic products in treating various disease models.
From: Emerging understanding of apoptosis in mediating mesenchymal stem cell therapy
Term | Origin | Induction method | Quantity | Administration time | Route | Delivered molecule(s) | Animal model | Recipient species | Ref. |
|---|---|---|---|---|---|---|---|---|---|
Apoptotic MSCs | Human ADMSCs | Serum deprivation | 1.2 × 106 cell-derived | 30 min, 6 h, and 18 h after model establishment | i.v. | None | Sepsis syndrome | Rat | |
Apoptotic MSCs | Human ADMSCs | Serum deprivation | 1.2 × 106 cell-derived | 30 min, 6 h, and 18 h after model establishment | i.v. | None | AKI | Rat | |
Apoptotic MSCs | Human DPSCs | H2O2 | 4.0 × 106 cell-derived | Immediate after model establishment | i.v. | None | GvHD | Mice | |
Apoptotic MSCs | Human BMMSCs | Anti-Fas and granzyme B | 1.0–2.5 × 106 cell-derived | 1 h after model establishment | i.p. i.v. | None | GvHD | Mice | |
MSC-derived EVs | Mice Gingival and skin MSCs | TNF-α | 40 μg | 1 d after model establishment | Submucosal injection | IL-1RA | Gingival wound | Mice | |
Apoptotic bodies | Mice BMMSCs | STS | 50 μg | 0 d, 3 d, and 7 d after model establishment | Local administration | None | Skin wound | Mice | |
Apoptotic bodies | Mice BMMSCs | STS | 4.0 × 106 ApoBDs | Once a week for 4 weeks | i.v. | miR-328-3p RNF146 | Osteoporosis | Mice | |
Apoptotic bodies | Rat and mice BMMSCs | STS | 100 μg | 2 weeks after model establishment | Intramyocardial injection | None | MI | Rat | |
Apoptotic EVs | Mice thymocyte and Jurkat cells | UV-irradiated | 20.0 × 106 or 40.0 × 106 cell-derived | 1 d before model establishment | i.p. | None | Colitis | Mice | |
Chimeric apoptotic bodies | Mice T-cell membrane with mesoporous silica nanoparticles | STS | 100 μg | 3 d, 5 d, 7 d, and 9 d after model establishment | i.v. | miR-21 and curcumin | Colitis and cutaneous inflammation | Mice |
